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In this thesis, we har.e explored the concept of drug targeting for the tÍeatment of
l ir.er cirrhosis. This fatal disease is currently among the top ten causes of death in the
\X'estern World and can not be treated propedl' with druqs. The onll' effectir.e
treatment to date is a liver transplantation. The lack of donor organs and thc
complexity of the surgical procedures, h{)we\.er, pre\rent rvidespread use of this
treatment. Pharmacological inten ention has failed up until no'w because of
insufficient uptake of drugs in thc target cells or extrahepatic side-effects, or a
combination of both. Organ or cell-specific targeting of drugs may circum\rent these
problerns.
l,jver cirrl'rosis is a disorder tl'rat is characterized by the deposition of large
amounts of extracellular matrix components like collagens (1). The fibrotic process
leading to lir.er cirrhosis is inducccl by the concerted action of many cell qpes and is
regulated by m2ny mediators. lnciting stimuli like 'u.iruses (hepatitis B, C), toxins
(alcohol, drugs), bile obstruction or metabolic disorders may damage hepatoo'tes and
calrse tl-re activation of other resident hepatic cells like I(upffer cells, sinusoidal
endothelial cells, and hcpatic stellate cells, or infiltrating inflammator)' cells. Chronic
activation of this inflammat()ry' process leads to an irreversible accumulati<>n of
extracellular matrix. In particular, the sinusoidal endothelial and l{upffer cells pla1. an
important roie in continuing the inflammator)' process b1' releasing a cascadc of
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inflammatory mediators: prostaglandins, leukotrienes, cytokines, chemokines, and
oxygen radicals.
Pharmacological intervention rvith several anti-inflarnmatorv drugs has onlr, met
with limited success. Some of the drugs (corticosteroids) were able to slow down the
discase progress in some cases (autoimmune hepatit is, primarl 'bil ian' cirrhosis), but
their use was hampered by the severe side-effects (2,3). By targeting anti-
intlzr.mmatory clrugs to endothelial and Í{upffer cells oi the lir.er the efficao' of these
drugs mar.be increased while avoiding the side-effects elservhere in the body.
For the drr-rg targeting studics described in this thesis rve used of two kinds of
anti-inflammat()r\r cln-rgs, napÍoxen and clexamethasone. Naproxen is a nonsteroidal
anti-inflammatory drug, related to aspirin. lt inhibits the enzyme cy'c1o-ox1'gcnzlse
v'hich is inr.olvecl in the st'nthesis of prostaglanclins. The side-effccts of naproxen are
usually mild, but during cirrhosis it can cause serious problems in the kiclnev. Its
pha,rmacokrgical potential, hole\.er, is also lirnitecl, because it onlt' inhibits thc
procluction of prostaglandins. Dexamethasone is a steroidal anti-inflammat()ry clrug
derivecl f iom the hormone cortisol. This cortic<tsteroid is a \-ery p()tent anti-
inflammatory drug because jt inhibits the production of rnany inflammatory
mediators. These include cy'tokines, chemokincs, prostaglanclins, leukotrienes, anc
oxvgen r:rclicals. This effectiveness, however, coincides s,ith serious siclc-effects,
espe cially during long-term use. Dexame thasone , for instancc, can cause
oste()porosis, an increasecl susceptibil i tr. to infections, ancl cliabetes. To ar'oid these
problems we ain-red at the targeting of naproxen and clexamethasone to the relo'ant
cell t1'pes.
In the studies presentcd in tl-ris thesis, we succeeclcd in clelivering naproxcn and
dexametl-rasone to endothelial and I{upffer cells using human serum albumin (HSA)
and its mannosylatecl derivatir.e. E,ndothelial and l{upffer cells have sca\renÉler
receptors that remo\re negatir..ely chargcd proteins and protcins rvith increased
h1'drophobicin' lrom the circurlation. For naproxen it had alrcadv bcen shr>rvn that
coupling of naproxen to HSA changes HSA into a substrate fctr these sca\renger
receptors (a). The coupling of napr,rxcn t() positivclv charged amino grolrps in the
HSA-molecule increases the rclatir.e negatir.c chargc. In addition, the naproxen
gr()uPs acld extra hl'drophobiciq, to the molecule. Likervise, wc anticipated that a
similar couplinu of clexamethasone to l lSA rvould cause uptakc bv the same
scavengcr recept()rs. We therefore also s1'nthesiscd a coniugate of dexamethasone
coupled to HSA.
To stud1, thc e f cts of targeting of dexamethasone specificallv to l{upffcr cells rve
cler.elopccl an()ther drug targeting prcparxtion using mannosl'lated HSA. Prer.ious
stuclies har.c shown that l\ ' IanrI,-HSA (10 molecules of the sr-rgar mannose coupled to
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1 molecule of HSA) is specifically taken up by the mannose receptors on I{upffer
cells (5). Dexamethasone v/as therefore coupled to this neoglycoptotein to achieve
specific targeting to I(upffer cells.
As mentioned before, previous studies showed that naproxen coupled to HSA
QNapz:-HSA) is taken up specifically by endothelial and l(upffer cells. After cellular
degradation, active naproxen was shown to be released. However, this active
naproxen was not the original naproxen, but naproxen-lysine. This degradation
product fortunately had the same activity profile as naproxen. Chapter 3 describes a
follow-up study with Napz:-HSA. This study was conducted to gain insight in the
pharmacokinetic behaviour of coupled naproxen. This information is needed for the
practical application of drug targeting preparations. Coupling of naproxen to HSA
distinctly altered the kinetic properties of naproxen. It was removed from the blood
stream at a much highet r^te th^n uncoupled naproxen (tz: 60+11 min vs. 1 52+44
min). Liver targeting of Napz:-HSA 'was cleady demonstrated: 180 min after
iniection, the naproxen content in the liver was 30 times highet for a dose Napz:-
HSA as compared to an equimolar dose of free naproxen. The elimination of
naproxen from the body had also changed dramattcally after coupling to HSA. Free
naproxen is mainly excreted by the kidneys (95o/r). HSA-coupled naproxen, however,
was predominantly excreted in bile as napÍoxen-lysine. The biliary ^ppe^rance of
Nap-lysine, observed after injection of the HSA-conjugate, had a considerable lag
time (20 min). Injected naproxen-lysine, on the other hand, appeared almost
immediately in bile. This difference of 20 min probably reflects the time necessary for
endocytosis, proteolytic degradation and transportation of naproxen-lysine through
the hepatocytes to the bile. The concentration of active naproxen in the target cells is
not exclusively dependent on the rate of uptake in the cells. This concentration is
also largely dependent on the degradation rate of the conjug te, the liberation of
naproxen-l)'sine, and its r^te of elimination.
In uiuo studies, in collaboration with the group of Ptof. J. Reichen in Bern, showed
a clear protective effect of Napz:-HSA during acute intrahepatic inflammation (6).
However, the chronic hepatic inflammation undedying [ver fibrosis, would probably
benefit more from potent anti-inflammatory drugs like dexamethasone, with a long
biological haif life. \il1'e therefore decided to concentrate our efforts on the targeting
of dexamethasone. This drug was coupled to HSA and Manro-HSA with a succinate
spacer linking dexamethasone to the protein. The spacer ensured the release of native
dexamethasone after degradation of the protein. \)íe developed two conjugates of
dexamethasone that we used in further studies: Dexaro-HSA (chapters 4, 5, 7 and 8)
and Dexas-Manro-HSA (chapter 6).
In chapters 4 and 6 the tissue and intrahepatic distributions of both conjugates
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were studied in healthy rats and rats with liver cirrhosis. Cirrhosis was induced by
ligation of the bile duct (BDI), which causes a quick and reproducible tlpe of
fibrosis of the liver. Ten minutes after injection of either dexamethasone coniugate,
about 70n/,,' of the dose had been taken up by the liver. No differences were found
berween healthl 'rats and BDI--rats. Dexaro-HSA distributed to both endothelial and
I{upffer cells, rvhereas Dexas-Manro-HSA had mt>stly been taken up b,v I(upffer cells.
Uncoupled dexamethasone rvas also taken up b,l' the liver. Most of this uptake,
hower.er, was found in the hepatocvtes, the cells responsible for the elimination of
dexamethasone from the bodv.
The release of actiue dexamethasone from the proteins was tested in an in uilro
s)'stem with precision-cut liver slices. In liver slices the cells are unaffected by
isolation and culture procedures and still l-rave their normal cell-cell contacts (7). The
effect of anti-inflammatory preparations can be studied by the inhibition of mediator
release after activation of resident cells with lipopolysaccharide [,PS). Both
conjugates inhibited the release of the int-lammatory medtato( tumor necrosis fàctor
alpha (TNFU) after LPS-incubation more effectively than free dexamethasone. This
indicates that active dexamethasone is indeed released rvithin the target cells.
The release of actir.e dexamethasone was confirmed with another t)'pe of
experiment in chapter 5. I{upffer cells from untreated rats or rats that had received
Dexaro-HSA were isolated and subsequentl)' incubated with LPS. The I(upffer cells
of the untreated rats released TNFU afler I-PS stimulation, whereas the I{upffer cells
of the Dexaro-HSA-treated rats did not respond to I-PS-stimulation.
In addition to these in t,iÍro studies, rve also demonstrated tl-re release of actil'e
dexamethasone in BDI--rats in uiuo (chapter 4). These rats were found to be very
sensitive to LPS. A small dose of this toxin caused the release of lethal amounts of
inflammatory mediators. BDL-rats treated rvith 10 mg.kgt Dexart,-HSA, however,
sun'ivecl the dose of LPS up to the end of the experiment. This, again, indicates the
release of active dexamethasone.
A study investigating the kinetic properties of Dexarr,-HSA is described in
chapter 5. At a dose below receptor saturation (3 mg.kg1) a rapid remor,'al of the
conjugate from the blood was found in both healthy and cirrhotic rats (t'; 6.1.!1.6
min vs. 6.6!1.5 min respectively). None of the determined k-rneuc parameters (t,,;,
clearance, \'olume of distribution) were significantiy different benveen healthy and
cirrhotic rats. The involvement of the scavenger receptors in the uptake of Dexaro-
HSA was demonstrated bf its reduced uptake in rats pretreated with polyinosinic
acid, an inhibitor of scavenger receptors. The kinetic profile of Dexas-Manr,r-HSA
and the receptor type involved in its uptake have not been studied )'et, due to the
technical problems encountered in attempts to analyse this compound in blood.
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Since we found uptake of our dexamethasone conjugates and release of active
dexamethasone in the target cells, we continued with testing these preparations in
rats rvith liver fibrosis. The biological activiq' of dexamethasone has a very long half
Itfe (36-72 hours), wc therefore clecided to treat BDL rats three times a rveek with 10
mg.kgl Dexaro-HSA (chapter 5). This dose had previously been shown t() protect
IIDL-rats against LPS-induced toxiciry. During BDl-induced liver fibrosis, however,
10 mg.kg-1 Dexaro-HSA induced weight loss and caused the animals to die within a
rveek. Therefore the dose was reduced hundred-fold to 0.1 mg.kg, Dexaro-HSA and
the experiment was repeated. This time we also treated rats with an equimolar
amount of the Dexas-Manr3-HSA conjugate, which amounted to 0.2 mg.kg'
(chapter 6).
In these cxperiments we did not find signs of overdosing in the rats treated with
either preparation. Dexar,,-HSA and Dexas-Manro-HSA did cleady shorv effects on
the extent of intrahepatic inflammation. Intrahepatic inflammation was determined as
the number of cells producing reactive ox)'gcn species (ROS). Activated I{upffer cells
produce R()S and release chemokines to attract neutrophils that also produce ROS.
Dexamethasone has been shorvn by others to inhibit both ROS-and chemokine
production. Thc l ivers of BDL-rats treated with the conjugares contained less ROS-
producing cells as compared to livers of untreated BDI--rats or BDL-rats treated
with uncoupled dexamethasone. However, the reduction of the hepatic inflammation
did not have the desired effect on the iibrotic process in these livers. The livers of
the rats treated rvith Dexaro-HSA and Dexas-Manro-HSA were found to contain even
nore collaqen when compared to the Uvers of untreated rats. For Dexai-Manro-HSA
rve tried to establish the mechanism behind this increase (chapter 6). The collagen-
increasing effect of dexamethasonc \À/as not likely to be related to an increased
production of transf<rrming grorvth factctr beta (TGFB), the m^lor profibrotic growth
fàctrrr. Nor was it likely' to be related to an decreased production of interleukin- 1.0, a
r.ery import^nt anti-inflammatory' cytokine. Dexamethasone, however, was found to
stimulate the mRNA expression of t issue inhibitor of metalloproteinase-1 (TIMP-1).
This factor, also produced by I{upffer cells, inhibits the enzyme collagenase, which
degrades collagens. During the f-ibrotic process the producrion of collagen is already
far,'oured over the degradation. The increase in TIMP-1 seen after treatment with
targeted dexamethasone can shift the balance towards excessive collagen production
even more.
A further study in which BDL-rats 'were treated with even lower amounts of
Dexaro-HSA (0.02 and 0.01 mg.kg') is described in chapter 5. These doses did not
have a demonstrable effect on either hepatic inflammation or collagen deposition.
The amount of dexamethasone in the target cells apparently did not reach levels for
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sigruficant biological actvtty in these cases.
An unexpected finding was the fact that the c^rrret Manro-HSA (without
dexamethasone coupled to it) also affected hepatic inflammation and fibrosis. The
livers of BDL-rats treated with this carrier showed a dramatic increase in hepauc
inflammation and collagen deposition. To our knowledge, the intrinsic effect of this
neoglycoprotein has not been reported before. In chapter 6 we speculate that this
observation may be related to the disease rnodel we have been using. Onl1, I{upffer
cells in diseased livers express the receptor for LPS, the CD14 receptor (8). Upon
ingestion of mannose-containing macromolecules, the mannose receptor has been
reported to activate cells in conjunction with the CD14 receptor (9). This may
explain the increase in ROS-production found for Manro-HSA and may be indirectly
responsible fot the incteased collagen deposition. Studies examining the use of this
type of drug targeting preparation in nondiseased livers would therefore not reveal
this effect.
A potential probiem with the use of protein-based carriers ma,y be their
antigeniciq.. Especially in the case of targenng to sinusoidal endothelial and I(upffer
cells that have been reported to be antigen-presenting cells (10), thus increasing the
risk of immunogenic responses. Rats treated once a week for three months with
Dexaro-HSA (chapter 5) or Dexas-Manro-HSA (unpublished observation) indeed
exhibited high antibodl. titers after one month. Treatment for more than a month,
however, caused à secondary decrease in antibody titers sug;esting tolerance
induction.
Since treating cirrhosis in humans is the ultimate goal of our efforts, rve also
investigated distribution and efficacy of Dexar,,-HSA in human liver tissue (chapters
7 and 8). Studies in experimental animals may not adequately predict the behaviour
of drugs in humans. Testing in humans is therefore essential, but unfortunately such
experiments are often not possible. \íe used healthy as well as cirrhotic human liver
tissue to study the uptake of Dexaro-HSA in the human condition. As found in the
rat studies, sca\renger receptors u/eÍe responsible for the uptake of Dexaro-HSÀ in
human endothelial and Iiupffer cells. In healthy human liver tissue both cell types
were found to have taken up the conjugate. In cirrhotic human liver tissue, however,
only I(upffer cells were responsible for the uptake. This difference with the situation
rn r^t livers arvaits further clarification yet. The release of acti\re dexamethasone in the
target cells was demonstrated in s[ces of human lir.ers incubated with LPS and
Dexaro-HSA. Slices incubated with onll'LPS upregulated the mRNA expression of
inducible NO synthetase (iNOS), the enzyme responsible for the production of NO
radicals. Coincubation with Dexaro-HSA completely abrogated the upregulauon of
iNOS. Dexamethasone has been reported to inhibit iNOS expression, indicating that
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active dexamethasone is released within the slice. These results all suggest that the
handling of Dexaro-HSA in human livers is probably not very different from the
handiing rn r^t livers.
Conclusions
The studies described in this thesis represent the entire process of developing drug
targeting preparations: from the synthesis of such preparations to their testing in
diseased animals and human tissue @oth healthy and diseased). Drug targeting has
often been proposed as the solution to problems of low efficacy of drugs and side -
effects caused elsewhere in the body. However, these aspects are seldom tested in
appropriate disease-models. In the present studies, we therefore tested the concept of
drug targeting as a possible treatment for lir.er cirrhosis. Fibrosis of the liver, leading
to liver cirrhosis, is a muitifactonal process, in which both endotheiial and I(upffer
cells have been identified as key players in the inflammation underlying liver fibrosis.
To target anti-inflammatory drugs to these cell types, we prepared conjugates of
naproxen and dexamethasone with albumin. Using these preparations we were able
to selectively deliver actiue naproxen and dexamethasone to endotheiiai and l{upffer
cells in rats. For dexamethasone we could confirm this in human liver tissue as well.
Treatment of rats with biie duct ligation-induced liver fibrosis with the
dexamethasone conjugates was studied in further detail. Both Dexaro-HSA and
Dexas-Manro-HSA were able to inhibit intrahepatic inflammation associated with
liver fibrosis. They faiied, however, to reduce the collagen deposition within the liver.
\X/e er.en found an increase in rats tÍeated with the dexamethasone conjugates most
likely caused by stimulation of TIMP-1 expression by dexamethasone. The selective
cellular delivery of this corticosteroid with its broad activity profile may therefore not
provide sufficient pharmacological selectivity to shift the overall cytokrne/autocoid
levels to an antifibrotic state.
These results, however, do reveal one other interesting aspect of drug targeting:
specific cellular inten'ention strategies in a disease like liver fibrosis can shed light on
the role of the particular celi tlpes in the pathogenesis. Our results indicate that in
liver fibrosis the endothelial and I(upffer cells may be responsible for continuing
hepatic inflammation, but they also ^ ppe^r to have an antifurotic role.
The immunogenicity of these drug targeting preparations does not appear to be a
major problem. Multiple injections over a prolonged period of time only led to a
transient rise in antibody titers, suggesting tolerance induction.
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